Methods for predicting pregnancy outcome in a subject by hCG assay
The present invention provides a method of predicting pregnancy outcome in a subject by determining the amount of an early pregnancy associated molecular isoform of hCG in a sample. The present invention further provides a method for determining the amount of early pregnancy associated molecular isoforms of human chorionic gonadotropin (hCG) in a sample. The present invention also provides a diagnostic kit for determining the amount of early pregnancy associated hCG in a sample. The present invention additionally provides an antibody which specifically binds to an early pregnancy associated molecular isoform of human chorionic gonadotropin. Finally, the present invention provides methods for detecting trophoblast or non-trophoblast malignancy in a sample.
1. A method for detecting Down's syndrome in the fetus of a pregnant subject comprising:
(a) contacting a sample from the subject with a capturing antibody which specifically or preferentially binds to nicked hCG, under conditions permitting formation of a complex between the capturing antibody and the nicked hCG;
(b) determining the amount of complexes formed in step (a) thereby determining the amount of nicked hCG in the sample; and
(c) comparing the amount of nicked hCG in the sample determined in step (b) with the amount determined for a normal pregnant subject, wherein the elevated level of nicked hCG in the sample as compared to that in the normal pregnant subject is indicative of Down's syndrome in the fetus.
2. The method of claim 1 , wherein the capturing antibody is B151.
3. The method of claim 1 , wherein the complex formed in step (a) is detected by a detection antibody.
4. The method of claim 3 , wherein the detection antibody is B207.
5. The method of claim 3 , wherein the detection antibody is labeled with a detectable marker.
6. The method of claim 1 , wherein the sample is a urinary sample or a blood sample.
7. A method for determining the amount of nicked hCG in a sample comprising:
(a) contacting the sample with a capturing antibody which specifically or preferentially binds to nicked hCG under conditions permitting formation of a complex between the capturing antibody and the nicked hCG, wherein the capturing antibody is B151; and
(b) determining the amount of complexes formed in step (a) thereby determining the amount of nicked hCG in the sample.
8. The method of claim 7 , wherein the complex formed in step (a) is detected by a detection antibody.
9. The method of claim 8 , wherein the detection antibody is B207.